Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 23924008)

1.

Toward new treatments for mantle-cell lymphoma?

Zucca E, Bertoni F.

N Engl J Med. 2013 Aug 8;369(6):571-2. doi: 10.1056/NEJMe1307596. No abstract available.

PMID:
23924008
2.

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

Zhang L, Newberry KJ, Wang M.

Expert Rev Clin Immunol. 2013 Jun;9(6):495-7. doi: 10.1586/eci.13.31. No abstract available.

PMID:
23730878
3.

Ibrutinib approved for mantle cell lymphoma.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF1. doi: 10.1158/2159-8290.CD-NB2013-172. Epub 2013 Dec 12.

4.

A breakthrough in mantle cell lymphoma.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2014 Feb;25(15):8. No abstract available.

PMID:
25122938
5.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.

N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.

6.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Brown JR.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24. Review.

PMID:
23656200
7.

Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.

McDermott J, Jimeno A.

Drugs Today (Barc). 2014 Apr;50(4):291-300. doi: 10.1358/dot.2014.50.4.2133570. Review.

PMID:
24918646
8.

Ibrutinib for the treatment of mantle cell lymphoma.

Shah N, Hutchinson C, Rule S.

Expert Rev Hematol. 2014 Oct;7(5):521-31. doi: 10.1586/17474086.2014.951323. Epub 2014 Aug 27.

PMID:
25158606
9.

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Wiestner A.

J Clin Oncol. 2013 Jan 1;31(1):128-30. doi: 10.1200/JCO.2012.44.4281. Epub 2012 Oct 8. No abstract available.

10.

A new era of treatment for chronic lymphocytic leukaemia?

Brown JR.

Lancet Oncol. 2014 Jan;15(1):3-5. doi: 10.1016/S1470-2045(13)70558-8. Epub 2013 Dec 10. No abstract available.

PMID:
24332240
11.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

Burger JA, Buggy JJ.

Leuk Lymphoma. 2013 Nov;54(11):2385-91. doi: 10.3109/10428194.2013.777837. Epub 2013 Aug 28. Review.

PMID:
23425038
12.

Overcoming mantle cell lymphoma's ibrutinib resistance.

Sinha G.

J Natl Cancer Inst. 2014 Nov 23;106(11). pii: dju394. doi: 10.1093/jnci/dju394. Print 2014 Nov. No abstract available.

PMID:
25421347
13.

Bone. Regulating osteoclast differentiation to prevent bone loss.

Jones B.

Nat Rev Rheumatol. 2014 Feb;10(2):66. doi: 10.1038/nrrheum.2013.206. Epub 2013 Dec 24. No abstract available.

PMID:
24366319
14.

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L.

Blood. 2013 Oct 3;122(14):2412-24. doi: 10.1182/blood-2013-02-482125. Epub 2013 Aug 12.

15.

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.

Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL.

Br J Haematol. 2014 Sep;166(6):849-61. doi: 10.1111/bjh.12974. Epub 2014 Jun 24.

PMID:
24957109
16.

Ibrutinib approved for the treatment of mantle cell lymphoma.

Small S.

Clin Adv Hematol Oncol. 2013 Dec;11(12):808. No abstract available.

PMID:
25016625
17.

Aurora kinase inhibition as an anticancer strategy.

Hilton JF, Shapiro GI.

J Clin Oncol. 2014 Jan 1;32(1):57-9. doi: 10.1200/JCO.2013.50.7988. Epub 2013 Sep 16. No abstract available.

18.

Imbruvica--next big drug in B-cell cancer--approved by FDA.

Guha M.

Nat Biotechnol. 2014 Feb;32(2):113-5. doi: 10.1038/nbt0214-113. No abstract available.

PMID:
24509736
19.

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS.

Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272. No abstract available.

PMID:
25498454
20.

Crizotinib in anaplastic large-cell lymphoma.

Gambacorti-Passerini C, Messa C, Pogliani EM.

N Engl J Med. 2011 Feb 24;364(8):775-6. doi: 10.1056/NEJMc1013224. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk